Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (408 reviews)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

408 publications

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Selleck's Dactolisib (BEZ235) has been cited by 408 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 35(1):108940

PubMed: 33784499 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5736

PubMed: 34086347 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2778

PubMed: 34204960 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00254-3

PubMed: 34111400 ( click the link to review the publication )

Clin Sci (Lond), 2021, CS20210571

PubMed: 34282832 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:621906

PubMed: 34124031 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:2173-2186

PubMed: 33758505 ( click the link to review the publication )
Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00805-X

PubMed: 34303705 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Neuroscience, 2021, S0306-4522(21)00070-1

PubMed: 33577953 ( click the link to review the publication )

SLAS Technol, 2021, 24726303211008858

PubMed: 33880947 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Biol Pharm Bull, 2021, 10.1248/bpb.b21-00531

PubMed: 34602526 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )
J Mol Cell Biol, 2020, 12(8):644-653

PubMed: 31065693 ( click the link to review the publication )

Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )
Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )
Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )
Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )

Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )
Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )
Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cancers (Basel), 2017, 9(9)E125

PubMed: 28926938 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )
Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

Cancer Lett, 2016, 374(2):250-60

PubMed: 26921131 ( click the link to review the publication )
J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )
Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(34):54883-54896

PubMed: 27448972 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )
Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )
Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(349):ra102

PubMed: 25351247 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )
Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

J Biol Chem, 2013, 288(41):29821-35

PubMed: 23963458 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )
J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NEDqXm9CdnSrbXnjdo9jcWGuIFHzd4F6		MnvwNVghcA>?	M3fBSGROW09?	MYDBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IIfpeIghTUN3MDDv[kAxNjByMkWg{txO	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
MCF7	NXvPSlRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqwMlAyNTFyMDFOwG0>	MlL4OFghcA>?	NUTvbm1uTE2VTx?=	NYj3Uoh1UUN3ME2wMlc{KM7:TR?=	MkDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{G5NFQoRjJ\|OEexPVA1RC:jPh?=
HCT116	NELjT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXZbYQxNjBzLUGwNEDPxE1?	NVra[ZJCPDhiaB?=	NVLMVm9PTE2VTx?=	MnLrTWM2OD1zLkG2JO69VQ>?	M1;1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA1Lz5{M{i3NVkxPDxxYU6=
U87MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPZOZoxNjBzLUGwNEDPxE1?	MnTPOFghcA>?	MYrEUXNQ	NFXoWVFKSzVyPUGuN\|Ih\|ryP	NXHzdXNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|E6ODRpPkKzPFcyQTB2PD;hQi=>
HBC4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\tdVAvODFvMUCwJO69VQ>?	M1zkc\|Q5KGh?		NHPGTGRNd2diR1m1NF0uQC54MTDN	MlHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
BSY1	M1qzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\EVFAvODFvMUCwJO69VQ>?	M1XtblQ5KGh?		MWjMc4chT0l3ME2tPE41QCCP	MoTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HBC5	NXfXdVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3eyOlAvODFvMUCwJO69VQ>?	M4XmTFQ5KGh?		NWH6[413VG:pIFfJOVA:NTdwOEegUS=>	M3rCW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MCF7	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuwMlAyNTFyMDFOwG0>	MoDZOFghcA>?		M1;zc2xw\yCJSUWwQU05NjF4IF2=	M1m1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MDA-MB-231	M{HzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PGeFAvODFvMUCwJO69VQ>?	MnLqOFghcA>?		MX\Mc4chT0l3ME2tPE4xQSCP	MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
U251	NEPF[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlj2NE4xOS1zMECg{txO	NYLyTHZpPDhiaB?=		M2jmW2xw\yCJSUWwQU04NjZ4IF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF268	NIDNb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvSNE4xOS1zMECg{txO	M1XLflQ5KGh?		NXGyZ2RyVG:pIFfJOVA:NTdwOUKgUS=>	Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF295	NYL3fnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHUdW1zOC5yMT2xNFAh\|ryP	MmnNOFghcA>?		MkLkUI9oKEeLNUC9MVgvOzFiTR?=	NFHEPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SF539	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XwNlAvODFvMUCwJO69VQ>?	Ml;vOFghcA>?		NIPrNmNNd2diR1m1NF0uQC53OTDN	MljYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SNB75	NHr0Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFGwOYsxNjBzLUGwNEDPxE1?	MV[0PEBp		NGe1OmZNd2diR1m1NF0uQC53ODDN	NHLsNo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB78	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVGwMlAyNTFyMDFOwG0>	NFfZbGE1QCCq		MUHMc4chT0l3ME2tPE43PSCP	MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HCC2998	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljyNE4xOS1zMECg{txO	M4DqZVQ5KGh?		NH;mOm5Nd2diR1m1NF0uQC5yNTDN	M2PwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
KM12	NFy5O\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[wMlAyNTFyMDFOwG0>	NIOxWpg1QCCq		NG[3bmRNd2diR1m1NF0uPy53NDDN	M3L6R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HT-29	M1;mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWiwMlAyNTFyMDFOwG0>	MXq0PEBp		NVXJO5pmVG:pIFfJOVA:NTdwN{WgUS=>	NIjMZpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HCT15	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP6WYgxNjBzLUGwNEDPxE1?	MmXTOFghcA>?		MnHoUI9oKEeLNUC9MVgvODNiTR?=	M2HrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCT116	M1zvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHXT2JnOC5yMT2xNFAh\|ryP	M3zIfVQ5KGh?		NYjzd5BtVG:pIFfJOVA:NTdwNkGgUS=>	M2PvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H23	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;INE4xOS1zMECg{txO	Mon3OFghcA>?		NWPsWVAxVG:pIFfJOVA:NTdwNkSgUS=>	NF7uPHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H226	M3jEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDYV\|UxNjBzLUGwNEDPxE1?	NGXkWXM1QCCq		NU\uZWdnVG:pIFfJOVA:NThwNESgUS=>	NF;IfHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H522	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn3NE4xOS1zMECg{txO	NEDQTpA1QCCq		MkLaUI9oKEeLNUC9MVgvPDViTR?=	NG\0PXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H438	NHPNe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TKUFAvODFvMUCwJO69VQ>?	NXfEcZJ5PDhiaB?=		NHvRWlJNd2diR1m1NF0uQC5zMTDN	NFjsWGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
A549	NH7weZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLiPY13OC5yMT2xNFAh\|ryP	MorNOFghcA>?		NIO5Z3VNd2diR1m1NF0uQC5yNzDN	NWLtNJM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DMS273	NWT6PGdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKwMlAyNTFyMDFOwG0>	MXy0PEBp		MoHrUI9oKEeLNUC9MVcvQDBiTR?=	NULpTpFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DMS114	M3fVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2wMlAyNTFyMDFOwG0>	NU[xbpJ{PDhiaB?=		MV7Mc4chT0l3ME2tPE4{QSCP	NV7ZVXFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
LOXIMVI	M{X0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6xeJYxNjBzLUGwNEDPxE1?	Mlf3OFghcA>?		NHzRfGFNd2diR1m1NF0uQC54NjDN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR3	M3vZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojiNE4xOS1zMECg{txO	Mn35OFghcA>?		MX;Mc4chT0l3ME2tPE4yPyCP	M1vmNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR4	NUDLTWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XqdFAvODFvMUCwJO69VQ>?	NUPQTIFjPDhiaB?=		MmXjUI9oKEeLNUC9MVgvPThiTR?=	NVHxbW1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rkPFAvODFvMUCwJO69VQ>?	NEflOmU1QCCq		M1H5Tmxw\yCJSUWwQU04NjV5IF2=	NH;HcZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
OVCAR8	NXPCOXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HYbVAvODFvMUCwJO69VQ>?	MmCyOFghcA>?		MkG2UI9oKEeLNUC9MVcvQDRiTR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SKOV3	NYrVNHhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnztNE4xOS1zMECg{txO	MkHwOFghcA>?		NVnnc\|F3VG:pIFfJOVA:NThwNEGgUS=>	MknYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
RXF631L	NVLHfmRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvOcIl{OC5yMT2xNFAh\|ryP	MkHNOFghcA>?		M3LCeGxw\yCJSUWwQU05NjJzIF2=	M2TwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
ACHN	NVrqSm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPWNE4xOS1zMECg{txO	NVrDRYt3PDhiaB?=		M13XU2xw\yCJSUWwQU04Njl3IF2=	MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
St-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7TNE4xOS1zMECg{txO	NFrPb3Y1QCCq		MoKyUI9oKEeLNUC9MVcvPDdiTR?=	NF\IWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTMeZFZOC5yMT2xNFAh\|ryP	NITK[ZQ1QCCq		NXrHb5NFVG:pIFfJOVA:NThwNEGgUS=>	NIPBNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN7	M3[3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULTXJhFOC5yMT2xNFAh\|ryP	M{DsSFQ5KGh?		NHvWT\|ZNd2diR1m1NF0uPy54ODDN	NF;ZZow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN28	M1m1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYSwMlAyNTFyMDFOwG0>	NFn2Smg1QCCq		MmX1UI9oKEeLNUC9MVcvODdiTR?=	M3nwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN45	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmwMlAyNTFyMDFOwG0>	Mn3kOFghcA>?		NHTMeWdNd2diR1m1NF0uQC5\|NDDN	MoDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN74	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnG[WMxNjBzLUGwNEDPxE1?	MmDuOFghcA>?		MlXnUI9oKEeLNUC9MVcvPDJiTR?=	M2\2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
DU145	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vnflAvODFvMUCwJO69VQ>?	NIj4WHo1QCCq		NHq0SoRNd2diR1m1NF0uQC5zNjDN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
PC3	M3\0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOwMlAyNTFyMDFOwG0>	MWC0PEBp		MoXrUI9oKEeLNUC9MVgvPjZiTR?=	M3TR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
Trypanosoma brucei brucei	M3rXTWZ2dmO2aX;uJGF{e2G7	MnHsNlAxKG6P	NXrTXW1wOTJiaB?=	NWPCcYlUTE2VTx?=	MWrE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	MnrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
Trypanosoma brucei brucei	NUn4dlhPTnWwY4Tpc44hSXO\|YYm=		NGizZ3kyQCCq	NX7VZmtFTE2VTx?=	M3GybWlvcGmkaYTpc44hd2ZicnXj[ZB1d3JvbXXkbYF1\WRiZX7kc4N6fG:\|aYOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5idILhcpNn\XK{aX6geZB1[Wun	NEL0dVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVk1Pid-MkS4NFU6PDZ:L3G+
Trypanosoma brucei brucei	NWP1SZRuTnWwY4Tpc44hSXO\|YYm=	MlL0NlAxKG6P	MV[xNkBp	NXnWfoV{TE2VTx?=	M4rPOGVn\mWldDDvckB{eGirbnfvcZlt\WmwIHzleoVt	MmG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
Trypanosoma brucei brucei	M2HwTWZ2dmO2aX;uJGF{e2G7	MkHMNlAxKG6P	MmfJNVIhcA>?	NEjPb4FFVVOR	NFPhR4FG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	Mn\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
UM-UC-3	NYnqTmJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTNzNTDwUS=>	Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SBC-1	M4e1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG0emdKSzVyPUe0NkBxVQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MKN1	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jlbmlEPTB;Mj64JI5O	MnrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H720	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr3TWM2OD1\|LkW3JI5O	NHfWc\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BFTC-909	M3zFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfzTWM2OD1\|LkexJI5O	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BPH-1	NHnMUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTRwN{[gcm0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnFRnlKSzVyPUWuNFkhdk1?	NF;ueWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AN3-CA	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHRcYx5UUN3ME21MlU3KG6P	NXH5S5N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HN	NGTxNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXPPVNJUUN3ME21Mlk3KG6P	MmfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC2218	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzTTWM2OD14Lk[xJI5O	NV7jSmpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KP-4	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTdibl2=	M{PWZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-139	M3;2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTdwN{egcm0>	NXvpUIVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ETK-1	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Lw[WlEPTB;Nz64PEBvVQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzXc\|lKSzVyPUiuOFkhdk1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MHH-PREB-1	NUfqRWZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz4UpFKSzVyPUmuNVIhdk1?	NIOxeWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DU-4475	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TrdmlEPTB;OT60OEBvVQ>?	M2X0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1666	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzmOpVKSzVyPUmuO\|Ehdk1?	MlXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAMA-1	NW\1NW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTIV25qUUN3ME25Mlghdk1?	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TYK-nu	NHP0ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2H5Z2lEPTB;OT65OEBvVQ>?	NF\mVGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MFE-280	M2DJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:wXWlEPTB;OT65PUBvVQ>?	NGX3TWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A549	NFv3eVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TURWlEPTB;MUCuNVQhdk1?	NFLSbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
769-P	NIntOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX3O2hsUUN3ME2xNE41PCCwTR?=	M3;zUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
L-363	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTCbIg4UUN3ME2xNE43QSCwTR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES8	NGXpcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC3fVlMUUN3ME2xNE46KG6P	NGrxOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PA-1	M13IWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fKUGlEPTB;MUGuPFIhdk1?	NXH0PG9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Mewo	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTFzLkm5JI5O	NXviOoduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HSC-3	NGTGU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF{LkKxJI5O	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
H4	NIT5dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mke1TWM2OD1zMj62O{BvVQ>?	Ml3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fWRWlEPTB;MUKuO\|Ihdk1?	NHzRXJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1793	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7lWZBKSzVyPUGyMlgzKG6P	NH[5[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KARPAS-45	M2PsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP0cJE6UUN3ME2xN{42OSCwTR?=	MmDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GCT	NGTZd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF\|Lk[4JI5O	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EoL-1	NGXndFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLqTWM2OD1zMz65N{BvVQ>?	NXnnSXpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LB2241-RCC	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTF2LkCxJI5O	NHe3[2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES5	MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvsTWM2OD1zND63OEBvVQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LOXIMVI	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fjdWlEPTB;MUSuPVkhdk1?	M175dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COR-L105	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXRTWM2OD1zNT6wOEBvVQ>?	M3vyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
P12-ICHIKAWA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHNTWM2OD1zNT6xJI5O	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CHL-1	NVHpPYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TjcmlEPTB;MUWuOFUhdk1?	Ml\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
VMRC-RCZ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXLb2lKSzVyPUG1MlY{KG6P	NIPiVmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HH	M2n3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX6TWM2OD1zNT63JI5O	NGHMVno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NUGC-3	MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rHc2lEPTB;MU[uN\|Qhdk1?	NUDxUnhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EGI-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C2W2lEPTB;MU[uOFMhdk1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OS-RC-2	NUPVb\|BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFe5SpdKSzVyPUG2MlQ4KG6P	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-16	M1e0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTF5LkG1JI5O	MnuyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H209	NXjsVnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvscVVKSzVyPUG3MlI6KG6P	NIiyWFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
697	M3ziO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF5LkSzJI5O	NInhe4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-56MG	NEjZWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTF5Lk[5JI5O	NH6zTlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTF5LkizJI5O	NHHNXlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EW-16	NUTIe3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfyU5FKSzVyPUG4MlA1KG6P	NXGwU3k3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HGC-27	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\1OGlEPTB;MUiuNFYhdk1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES7	NELheYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LYRmlEPTB;MUiuNFkhdk1?	NELodHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HuH-7	NXr1UJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPXOXk{UUN3ME2xPE41KG6P	NXPndZM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BCPAP	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HM[mlEPTB;MUiuOlUhdk1?	M2\5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1710	NIHTZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[0[5JzUUN3ME2xPE44OiCwTR?=	NXSxV4VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
IST-MEL1	M1n6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF6Lke3JI5O	MmjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SF295	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHPTWM2OD1zOD65N{BvVQ>?	NI\jbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RPMI-7951	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTF7LkK4JI5O	M3\3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SF126	M1;EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LtXmlEPTB;MUmuOFEhdk1?	M4CxO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GAMG	M3PJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWj3UY1rUUN3ME2xPU41QCCwTR?=	NH;6ZWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KNS-81-FD	NGq5XFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF7LkW0JI5O	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RT-112	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrrOolKSzVyPUG5MlY3KG6P	M4rJc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DEL	M4D5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HuUWlEPTB;MkCuOFkhdk1?	NID0TWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CGTH-W-1	NVH1fXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLzTWM2OD1{MD62N{BvVQ>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HOS	NHfpT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:1TWM2OD1{MT6wOkBvVQ>?	NX;QV5V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES4	NHHJT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJzLkC4JI5O	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RXF393	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJzLkS1JI5O	NHvkSWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2030	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\1VWpKSzVyPUKxMlUzKG6P	M3vCT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
YH-13	NX\QU49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTXbVZKSzVyPUKxMlg5KG6P	NV25NWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-1080	NHzMT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTJzLkmzJI5O	M{\KWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-SNU-1	NXvl[HJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3i5W2lEPTB;MkGuPVUhdk1?	NHHOc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
G-402	NYL5Sm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mor1TWM2OD1{Mj6xOkBvVQ>?	NVW4emFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
786-0	NXizeWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkG2TWM2OD1{Mj6yPUBvVQ>?	NVyyOmpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ME-180	M33uPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJ{LkSzJI5O	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB69	MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7UTWM2OD1{Mj61N{BvVQ>?	NH;EV\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5	NWe5VGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXiRmlKSzVyPUKyMlk3KG6P	MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TGBC1TKB	NXjy[W55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33FcmlEPTB;MkOuNFUhdk1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW780	NETsS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\jcGlEPTB;MkOuNVMhdk1?	NWT1dXhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MG-63	M1r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzQbJZYUUN3ME2yN{41PSCwTR?=	NInCNpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BV-173	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ\|Lki3JI5O	M2m2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-51	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HGemlEPTB;MkOuPFkhdk1?	NUTI[JhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A375	NV7QU2xkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXhTWM2OD1{Mz65N{BvVQ>?	NETaXZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MEL-HO	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\wWm9KSzVyPUK0MlA1KG6P	MmrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EFO-27	NGPBZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJ2LkOzJI5O	NXniW\|ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Hs-578-T	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES5So5KSzVyPUK0MlU5KG6P	NUOwboFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NBsusSR	M3LHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJ2Lk[gcm0>	Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CTB-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHmz[IpKSzVyPUK0MlY4KG6P	NYnudFRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
FTC-133	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ3LkGgcm0>	NUPlVIxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MOLT-4	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\VTWM2OD1{NT6xNkBvVQ>?	M3XldVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HO-1-N-1	M{DLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fRSmlEPTB;MkWuNVUhdk1?	NHy3N3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES3	NEjmbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ3LkKyJI5O	M4P2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TI-73	NILOWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnCTWM2OD1{NT6yPEBvVQ>?	NGnhOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MPP-89	M4KwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDvWlR2UUN3ME2yOU4{OiCwTR?=	NVzZW\|JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-150	NIL3VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVW4O2lHUUN3ME2yOU45QSCwTR?=	NWfpPFZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LXF-289	M2GwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTOflZKSzVyPUK2MlA1KG6P	MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-LU-1	M3nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O0bWlEPTB;Mk[uNVchdk1?	MnnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HOP-92	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJ4LkS4JI5O	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuO9	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInpOGpKSzVyPUK2Mlc3KG6P	M4C3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW962	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7rTWM2OD1{Nj63OkBvVQ>?	MlnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RS4-11	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;tT4xKSzVyPUK2MlkyKG6P	MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H292	M2rpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7NTWM2OD1{NzDuUS=>	NVr2[5lTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DB	M{HSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJ5LkO2JI5O	NYnscotIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1088	NF\WVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi1N4pSUUN3ME2yPE4zQSCwTR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A204	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ6LkS3JI5O	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A3-KAW	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJ6Lk[0JI5O	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MV-4-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LNZmlEPTB;MkiuO{BvVQ>?	Mk\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES1	M1v3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJ6Lki0JI5O	M{LnVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ONS-76	NFXuW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mny0TWM2OD1{OT6wOUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-263MG	NFrFTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HpNmlEPTB;MkmuN\|Uhdk1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U-2-OS	NEG5SVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW2b4wyUUN3ME2yPU42KG6P	NH[4eow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
T98G	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF25WppKSzVyPUK5Mlg5KG6P	M1zQb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GI-ME-N	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XUe2lEPTB;MkmuPVEhdk1?	MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BHT-101	NYHFeGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\6bYxKSzVyPUOwMlA2KG6P	MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NOS-1	NV7pT4VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTNyLkGyJI5O	NH2yU4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AsPC-1	NH3l[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfDTWM2OD1\|MD6yJI5O	NYO4UpgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
QIMR-WIL	M{juTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITB[HFKSzVyPUOwMlYhdk1?	M4XuT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
JVM-3	M1HzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFP6[IhKSzVyPUOwMlg{KG6P	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KU-19-19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjmR5VCUUN3ME2zNU4yOyCwTR?=	NGqxbpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OVCAR-8	NUHlZWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrjU5htUUN3ME2zNU4zPiCwTR?=	MlXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BEN	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjJfFhQUUN3ME2zNU43OyCwTR?=	NXT2NIFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BE-13	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nidmlEPTB;M{GuPFIhdk1?	NEjHeW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EW-18	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTNzLki2JI5O	M{jIN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ECC10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLaTWM2OD1\|MT65OUBvVQ>?	NUjLXppSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CTV-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTN{LkiyJI5O	NGjnUVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-800	M4HZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG1c21JUUN3ME2zNk46OiCwTR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A2058	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mly5TWM2OD1\|Mz6yOUBvVQ>?	NYLXU4VkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
VM-CUB-1	M2LFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XLbmlEPTB;M{OuOFMhdk1?	NX3KWpU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Ca9-22	M{TjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIju[2lKSzVyPUOzMlU2KG6P	NGKyZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-684	NIrLTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1L2fWlEPTB;M{OuOVghdk1?	NYfyepR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RPMI-8226	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fZdWlEPTB;M{OuPFIhdk1?	NV;CN3MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-NEP-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTN2LkG1JI5O	MkPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Becker	NEXCNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\YV\|FKSzVyPUO0MlIyKG6P	NVXkeJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H28	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT0W2NpUUN3ME2zOE41PCCwTR?=	NHvofWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-120	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPTZWdKSzVyPUO0MlczKG6P	M3XzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-157	NH\GfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrOcXJKSzVyPUO1MlQyKG6P	NHHtVYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OVCAR-5	M{m5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXsTWM2OD1\|NT60O{BvVQ>?	Mn3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LAMA-84	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLiXIhUUUN3ME2zOU45PyCwTR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAKI-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzZUGM4UUN3ME2zOk41OyCwTR?=	MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Daoy	NFHjO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[2PGlEPTB;M{[uO{BvVQ>?	M4LpNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-62	NGrLTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTN4Lki2JI5O	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
8-MG-BA	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;iWHd1UUN3ME2zO{4zPSCwTR?=	NUPIZ5dXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
8505C	NUDC[Yt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXOTWM2OD1\|Nz61NUBvVQ>?	NFfsTlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	M2jnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETwVY9KSzVyPUO3MlU6KG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-39	NFSwcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jaTmlEPTB;M{euPUBvVQ>?	Mn\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MN-60	M{XaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL0S5J4UUN3ME2zO{46PiCwTR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RKO	NXno[GRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFriZnBKSzVyPUO4MlM{KG6P	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U251	NWTBW\|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTN6LkSzJI5O	MmHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SJSA-1	NGn2[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr1TWM2OD1\|OD61OEBvVQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-12T	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7SUYlJUUN3ME2zPE43KG6P	MlTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1419	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2n4fWlEPTB;M{iuO\|Ehdk1?	NUXJSJJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CO-314	M33rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2T6PWlEPTB;M{iuO\|Qhdk1?	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB1047-RCC	NEO5SGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rZZWlEPTB;M{iuPFEhdk1?	M4P5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A101D	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTGfpk5UUN3ME2zPE46PyCwTR?=	MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-175-VII	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33WeGlEPTB;M{muOVEhdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MZ2-MEL	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXhW5JEUUN3ME2zPU43PiCwTR?=	NHfaS3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB5	M4DaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTRyLk[0JI5O	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
G-401	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTRyLkiyJI5O	M{HBT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HT	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vCT2lEPTB;NEGuNFIhdk1?	NFjx[Xg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
8305C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL2RlNKSzVyPUSxMlg4KG6P	M3XVVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BHY	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTR{LkeyJI5O	NH;DS5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nSfWlEPTB;NEOgcm0>	NVnVSWoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
T-24	M4TKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnhTppYUUN3ME20N{45OyCwTR?=	MnzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EPLC-272H	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3KVJJKSzVyPUS0MlM6KG6P	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PSN1	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvBXGhHUUN3ME20OE41KG6P	NWTiN41PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2452	NWX1[ZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXiPJpKSzVyPUS0MlU5KG6P	M2DmOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KS-1	NHfDSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH33emtKSzVyPUS0MlY3KG6P	M3PYSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HD-MY-Z	NHXiRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jSS2lEPTB;NESuPVIhdk1?	NGfMZ4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KNS-62	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;1UZByUUN3ME20OU4{QCCwTR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NOMO-1	NF7rcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HKSWlEPTB;NEWuPFchdk1?	NYXWcJJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-HEP-1	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX6d\|JKSzVyPUS2MlA1KG6P	M2PHbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGR-1	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HVUmlEPTB;NE[uNVMhdk1?	M3zuSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7CWWlWUUN3ME20Ok4yPyCwTR?=	MnuwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-22	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HMRmlEPTB;NE[uNkBvVQ>?	M2TVdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1355	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2j0dWlEPTB;NE[uN\|Qhdk1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DOHH-2	NH\CZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTR4LkO3JI5O	MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A4-Fuk	NWHpZXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTOfGRLUUN3ME20Ok42OiCwTR?=	Mn[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PC-14	MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[4UFNQUUN3ME20Ok42PyCwTR?=	Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TE-5	M1XLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTR4Lki0JI5O	MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB996-RCC	M2LXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLOdHQ4UUN3ME20O{4yQSCwTR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1623	NVPWZ41{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTR5Lke2JI5O	NFPvNog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1155	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojTTWM2OD12OD6zNkBvVQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LoVo	MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS4b\|RIUUN3ME20PE41KG6P	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MCF7	NFLxdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPLZ2lWUUN3ME20PE42QCCwTR?=	NEfoV\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AGS	NWH0[YxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDOTWM2OD12OD63O{BvVQ>?	NGHBVXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PFSK-1	M4LPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHJTWM2OD12OT6wOkBvVQ>?	M1HZ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
22RV1	NF6yc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Pld2lEPTB;NEmuNFkhdk1?	MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COR-L23	M3vvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTR7LkG2JI5O	NVqyUI1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-283MED	NHrxRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K3NGlEPTB;NEmuOlEhdk1?	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW982	NX:y[3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\NTI9KSzVyPUS5MlkyKG6P	M3jHNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW620	NVmwTI42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fxfWlEPTB;NUCuN\|Yhdk1?	M2ixWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-140	NV7QNpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3XTWM2OD13MD61OUBvVQ>?	NH\ES4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GCIY	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3GwSGlEPTB;NUCuOlchdk1?	M1n4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MHH-ESS-1	NFW2ZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXWTWM2OD13MT65OUBvVQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-423MG	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjnZVFKSzVyPUWyMlA5KG6P	M3\5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SF539	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTV{LkO1JI5O	NEjnfGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RPMI-2650	M3XxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTV{Lk[5JI5O	M4XoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GR-ST	M1fVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofCTWM2OD13Mj64O{BvVQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
YKG-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVK3SIhvUUN3ME21N{BvVQ>?	NFvrfGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-MES-1	NVrIeYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTV\|LkK2JI5O	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HLE	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjqO2NFUUN3ME21N{41PyCwTR?=	MlfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RVH-421	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPFZodGUUN3ME21N{43PyCwTR?=	MorRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
C32	M1;aNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTV\|LkizJI5O	NYrVXVhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GB-1	M4Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1T6[GlEPTB;NUSuNkBvVQ>?	M3v4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNB75	NGnJXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3nWGN[UUN3ME21OE4zPiCwTR?=	NGjmboo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EM-2	M1zRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjJbXczUUN3ME21OE41KG6P	NVm0WFY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RH-1	NIHaVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf2TWM2OD13ND63JI5O	NInSOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NKM-1	M2KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfyfWNKSzVyPUW0MlgyKG6P	MlTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2405	NIr6UVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTV2Lki4JI5O	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-450	M{Ls[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTV3LkG2JI5O	NUTsT5dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A704	M4nCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTV3LkW5JI5O	NVPCU5hURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HAL-01	NFexXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTV3LkizJI5O	M2THOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-11	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTV3Lkm5JI5O	MnzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DOK	NVPGfYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHDNHFZUUN3ME21Ok4xOiCwTR?=	NYTHPXdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KY821	NV:0WmxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnH1TWM2OD13Nj6yJI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KGN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTrTWM2OD13Nj6zNkBvVQ>?	NX;ydFJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MC116	NYXIcnhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3WTWM2OD13Nz64JI5O	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PANC-08-13	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTvTWM2OD13OD6wNUBvVQ>?	NUi0NHZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KE-37	M4PpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\RRnJKSzVyPUW4Mlc4KG6P	NHG2b\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-410	M{nI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme5TWM2OD13OT60O{BvVQ>?	M3PIc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RO82-W-1	M{nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHU[5hKSzVyPUW5Mlkhdk1?	M1HWWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
M14	M2f0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTZyLkC0JI5O	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GI-1	NVHmSHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvOTWM2OD14MD6zJI5O	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ML-2	NGTkSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T1dmlEPTB;NkCuOlIhdk1?	NIrrWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BFTC-905	M4LEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzmS\|h7UUN3ME22NE43PSCwTR?=	NX7xdW5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DMS-273	M1HubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n0[GlEPTB;NkCuPFchdk1?	M1XMXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-361	NF;De4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTZzIH7N	NGLleYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MSTO-211H	M3Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTZ\|LkWxJI5O	NHTab\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MEG-01	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULuUHdFUUN3ME22N{42OiCwTR?=	NI\VTGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
M059J	M1nWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvLW\|NKSzVyPU[zMlU5KG6P	NXf5fWM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LN-405	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzwTIYxUUN3ME22N{45PSCwTR?=	NF\xSGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1581	NYj3bJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXNdY5KSzVyPU[0MlA{KG6P	MnvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TCCSUP	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGWwfWxKSzVyPU[0MlU{KG6P	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW872	M3zJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rIOGlEPTB;NkSuOVchdk1?	NXvPT21XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-510	M1HzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjITWM2OD14NT63OUBvVQ>?	MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1792	NEnlU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjNSlF4UUN3ME22Ok4yPSCwTR?=	MmrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW13	NHq4Oo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnmZpBKSzVyPU[2MlUhdk1?	M1fVd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-8	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTZ4LkWyJI5O	M1XscVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SCH	NWrSTY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr6R\|lKSzVyPU[3MlEhdk1?	M1zCTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NEC8	M{Pwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDDTWM2OD14Nz6yOEBvVQ>?	M17CXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuO-3N1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTZ5LkOxJI5O	Mlz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EFM-19	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTZ5LkWgcm0>	M4fqRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HEC-1	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTnTWM2OD14Nz61NkBvVQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
T47D	NU\LTGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGflTHNKSzVyPU[3Mlg4KG6P	Mni3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SNU-423	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33NbGlEPTB;NkeuPVghdk1?	NIjWNY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
WM-115	NYXQWmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrUTWM2OD14OD6xOEBvVQ>?	M4HGO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CaR-1	NF;KXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmixTWM2OD14OD6yOUBvVQ>?	Mn7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KU812	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjse4pKSzVyPU[4MlY6KG6P	MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
AM-38	NInnXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHXfpFSUUN3ME22PU4{OSCwTR?=	NXj1SFB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KOSC-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K5dGlEPTB;NkmuPVchdk1?	NHq1eXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MC-IXC	NX3rboZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X1TmlEPTB;N{CuNFghdk1?	NF;FTnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SCC-4	M4fXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjGW3VKSzVyPUexMlM5KG6P	M{j4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Calu-3	NEPWOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTdzLkm4JI5O	NEXkO4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RPMI-8866	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTd{LkiyJI5O	M37melxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OVCAR-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrpNHBUUUN3ME23N{4{PiCwTR?=	MlPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OAW-42	NULWNpBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfMTWM2OD15Mz6zPUBvVQ>?	Mkm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ATN-1	NUfUW4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjjVVFKSzVyPUezMlg4KG6P	NHrLO4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CHP-212	NXnGbHFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn72TWM2OD15ND65OUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
C2BBe1	M2ruc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrke2dKSzVyPUe1MlA{KG6P	M33MbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A498	M13icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P0eGlEPTB;N{WuNVUhdk1?	NFTyXWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SH-4	M2qzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTd3LkKxJI5O	NX\MTGgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SNU-449	NEHwcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTd3Lke5JI5O	NWTMcllkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RD	NX\qR2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\uTWM2OD15NT64OkBvVQ>?	M1zreVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PANC-03-27	NVGwUIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPk[ohKSzVyPUe2MlI2KG6P	NWPHS29lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
S-117	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13BbWlEPTB;N{[uNlchdk1?	NUDPToVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MEL-2	NI[0TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W4dmlEPTB;N{[uO\|Uhdk1?	MkLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LK-2	NHKzVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHFTWM2OD15Nz6wOUBvVQ>?	NHXE[HA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLyN4hwUUN3ME23O{41KG6P	M4Lt[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
647-V	NIXNTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO4UlFKSzVyPUe4MlA4KG6P	MmHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LU-134-A	M2npeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjzRpA2UUN3ME23PU4xOyCwTR?=	MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
5637	NGHJS\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTd7LkKzJI5O	MmLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1437	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnX4TWM2OD16MD61JI5O	Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H460	NVzNcGltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRThzLkKzJI5O	NXr0NGYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BxPC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRThzLkS2JI5O	NVPMeoRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv6SIxCUUN3ME24NU45PCCwTR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KINGS-1	NEXv[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3BTWM2OD16Mj6zNkBvVQ>?	NVrUeGxTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OCUB-M	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPOTWM2OD16Mj60NUBvVQ>?	NXKxfGlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KALS-1	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nHV2lEPTB;OEKuOVQhdk1?	NWTLSHd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OCI-AML2	M1HhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P4NmlEPTB;OEKuOlEhdk1?	M3K3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A253	NUnITIJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DRWmlEPTB;OEKuOlUhdk1?	NXLKemV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LCLC-97TM1	NXvXPYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTh{Lki2JI5O	MlvMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H520	NVPZOVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonQTWM2OD16Mz6wOkBvVQ>?	M3LvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
P30-OHK	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHtbWpSUUN3ME24N{42KG6P	NFvxVWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SBC-5	NF;xTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\zTWM2OD16Mz61NkBvVQ>?	NEn2Vng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCE-T	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUL1SWwyUUN3ME24N{44PCCwTR?=	M{TkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
JEG-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHaTWM2OD16ND6xJI5O	NIH2SGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KG-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nEOGlEPTB;OESuNlQhdk1?	NXHIS\|Y3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MIA-PaCa-2	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:5Z2xKSzVyPUi0MlU1KG6P	NHv4Xms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-33	M2r0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTh3LkC4JI5O	M4rRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
639-V	NYjpelNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7zeW1KSzVyPUi1MlQzKG6P	M3\IUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1048	NV\2Sm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTh4LkOxJI5O	M2nIcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1573	M{\zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEn6W5JKSzVyPUi3MlQ5KG6P	NEXkUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2228	NYXxb4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTh6LkK2JI5O	NY\Od\|YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NB14	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPSTWM2OD16OD6zJI5O	NH7BRmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SCC-25	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfJdm5vUUN3ME24PU45OiCwTR?=	M3:0b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A431	MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj4TWM2OD16OT65O{BvVQ>?	NEDOWpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SN12C	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTlyLk[yJI5O	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuCCT1	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TXd2lEPTB;OUCuO\|Yhdk1?	Mn\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LS-123	NUHTOmhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zlemlEPTB;OUKuNVghdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-85-1	NV3hZ4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rQbWlEPTB;OUKuOFghdk1?	MkHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES6	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfKTWM2OD17Mj64N{BvVQ>?	NX7MZ41jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H650	M2S0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW[yZm9sUUN3ME25OE4xQSCwTR?=	M3XQeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H446	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTWc\|JKSzVyPUm1MlEzKG6P	MlXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-13	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TudGlEPTB;OUWuO\|Uhdk1?	NI[0cJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HSC-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzZc4p4UUN3ME25OU45QSCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U031	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17M[GlEPTB;OU[uO\|Mhdk1?	NXHDZW1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLvTWM2OD17Nj64PEBvVQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GAK	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3S3UmlEPTB;OUiuPVMhdk1?	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-OV-3	M33wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXrdZNKSzVyPUGwNE4xPyCwTR?=	MofZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OMC-1	M1frXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnKOYtKSzVyPUGwNE4yQCCwTR?=	NUTESJlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TK10	NHXrb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFyMD6yNUBvVQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EKVX	M3vJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPhVZR{UUN3ME2xNFAvPiCwTR?=	NHj5SZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Detroit562	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGq3NHFKSzVyPUGwNk4yPyCwTR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SF268	NWfIfJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn0XXlKSzVyPUGwNk4{PCCwTR?=	NWHre5gzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SNU-387	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonDTWM2OD1zMESuNVchdk1?	M4fOSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-231	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PSb2lEPTB;MUC1MlA3KG6P	NWjqToh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1563	NVTOXoJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXNSG1DUUN3ME2xNFUvOThibl2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-502MG	NIXHZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrJO41KSzVyPUGwOU44KG6P	MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A2780	M1zYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHOTWM2OD1zME[uOFchdk1?	MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
IA-LM	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2H1Z2lEPTB;MUC3MlUyKG6P	MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-392MG	NHu1eWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrzTWM2OD1zMEeuOVQhdk1?	NXTMVpZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYCwRotoUUN3ME2xNFcvPzFibl2=	NUL3TZlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1990	NYXVOXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDxTHFKSzVyPUGwPE42PCCwTR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HEL	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\2TppKSzVyPUGwPU4zQSCwTR?=	M371WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1573	NXm5SodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHNdJpWUUN3ME2xNFkvOzFibl2=	MmXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1783	NWf1c\|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nqWmlEPTB;MUGwMlIzKG6P	NHTOeIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-680N	NYq3ZY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH6TWM2OD1zMUCuO\|Yhdk1?	Mn;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-N87	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrFTWM2OD1zMUGuNFQhdk1?	MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-28	NFLmZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjuXYtKSzVyPUGxNU42PSCwTR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BT-20	NUj4eml3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G2dGlEPTB;MUGyMlAyKG6P	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1648	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFzMzDuUS=>	NGDoSI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
no-11	NFTHNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXDTWM2OD1zMUOuNlghdk1?	M3TlPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MOLT-13	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTneVQ1UUN3ME2xNVMvPDRibl2=	MoC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2170	M{Cx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vIZ2lEPTB;MUG0MlUyKG6P	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HTC-C3	NYXzXFl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjwUGhKSzVyPUGxOk45PSCwTR?=	M4L5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-99A	NHrGRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fa[mlEPTB;MUG3MlIyKG6P	M1vHdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCC2998	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\kbWVKSzVyPUGxO{46OiCwTR?=	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB13	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L3dWlEPTB;MUG3Mlk6KG6P	NE\WZWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GT3TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\HXGJKSzVyPUGxPE4xQCCwTR?=	Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BT-549	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfoTWM2OD1zMUiuPVUhdk1?	NEfpUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H747	M1HyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\mTWM2OD1zMUmuN\|Qhdk1?	NIPhb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EW-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXke5BKSzVyPUGyNE4zKG6P	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB831-BLC	M3L6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPwbmNkUUN3ME2xNlAvPjNibl2=	M1\wSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NMC-G1	NXHHTlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Hs[2lEPTB;MUKxMlEyKG6P	NXTnRZJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-679	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfQcGRwUUN3ME2xNlIvOTVibl2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HL-60	M{PRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF{Mz6xJI5O	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MKN7	NEPrSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTF{Mz64N{BvVQ>?	M{nhXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RERF-LC-MS	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f1U2lEPTB;MUK0MlMyKG6P	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DMS-114	M4ntdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HIVGlEPTB;MUK1MlA6KG6P	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuP-T4	MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF{Nj65O{BvVQ>?	MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC2157	NYfXZWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHkcVk{UUN3ME2xNlcvPSCwTR?=	NID3NnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SKG-IIIa	NEPa[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPk[WRKSzVyPUGyPE45KG6P	MnPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCT-116	NWDVcYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\PTWM2OD1zM{CuOlQhdk1?	NGfQb249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BB30-HNC	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnCepB{UUN3ME2xN\|AvPzhibl2=	NFzMZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-270	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\OWmlEPTB;MUOwMlg5KG6P	NXT0WpB4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MFM-223	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;6OGtKSzVyPUGzNU42OSCwTR?=	NYHxdoYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NH-12	NEXP[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PuRWlEPTB;MUOyMlk6KG6P	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U-118-MG	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnHRWFKSzVyPUGzN{43OiCwTR?=	NI\EV4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ESS-1	NWfqcHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TIeGlEPTB;MUO1MlE5KG6P	NWnsOY96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-247MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\1TWM2OD1zM{WuNlEhdk1?	M3zCdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGROV-1	NH\UZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrVTWM2OD1zM{WuO\|Yhdk1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
C-33-A	NV3NdYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLiTWM2OD1zM{WuPVchdk1?	M2\YNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1693	NI\Bb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInD[IRKSzVyPUGzOk4yOiCwTR?=	NYnOfIt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MLMA	NYTpXo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF\|Nj61PEBvVQ>?	M13tXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-N-AS	NIHONFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3wOHpYUUN3ME2xN\|cvOTdibl2=	M171V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1755	M2qycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF\|OD64OUBvVQ>?	M{PhT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHP-134	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPKTWM2OD1zM{muOVUhdk1?	NYrYbHdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-513	NHGxc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF2MD65NUBxVQ>?	M2HqZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-12	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnKzTWM2OD1zNECuPVMhdk1?	NF23O3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KNS-42	NVS2fFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTOTWM2OD1zNESuN{BvVQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SJRH30	NXPSeWttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF2ND60OEBvVQ>?	NUf6XJl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1092	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXQSoRTUUN3ME2xOFQvPTJibl2=	M4m4O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
H-EMC-SS	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rtd2lEPTB;MUS2MlgyKG6P	NWLqemZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MEL-3	M2H5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoCyTWM2OD1zNEeuOVUhdk1?	NGHzVVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-N-FI	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnyyTWM2OD1zNEeuOVkhdk1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2126	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF2OD6xOUBvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1299	NH64clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjVNIxKSzVyPUG1NE4zOiCwTR?=	NXfHeZpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CFPAC-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLvTWM2OD1zNUCuOlYhdk1?	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H661	NUnxTWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF3MT6yOkBvVQ>?	NVjUOph1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-70	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGr3T21KSzVyPUG1NU44QSCwTR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW900	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF3ND62OUBvVQ>?	NWTQcmZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Ca-Ski	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmWwTWM2OD1zNU[uN\|khdk1?	M3ewTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HPAF-II	NHPYN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCwc4RXUUN3ME2xOVYvPDdibl2=	M1vpblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB2518-MEL	NGfXOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF3Nz6xJI5O	M4fIPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LC-2-ad	M4\oVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF3OD62NkBvVQ>?	NHvUTGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC1806	NX;ofocyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2raZWlEPTB;MU[3Mlg5KG6P	M1Xjb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
UACC-62	NH3LbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD4Z5ZNUUN3ME2xOlgvODlibl2=	NFnv[Fk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KM-H2	MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jYdWlEPTB;MUewMlU5KG6P	NXG4XGNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2347	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF5Mj63NkBvVQ>?	NVjG[VFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SCC-15	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn2TWM2OD1zN{OuOlYhdk1?	NXnBdYlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB49-HNC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv4TnJ5UUN3ME2xO\|MvQDFibl2=	NHHDcGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GMS-10	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkO0TWM2OD1zN{OuPVQhdk1?	NXTzNYV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2052	NX22e5dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrrTWM2OD1zN{SuPUBvVQ>?	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW626	M3i1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe3SGJKSzVyPUG3Ok4xPiCwTR?=	NFPoU2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-415	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vncWlEPTB;MUe2MlYyKG6P	M{X6PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Saos-2	NXrMOGp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfLdmhQUUN3ME2xO\|kvOzVibl2=	Mn7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DK-MG	M3X5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXiybWtmUUN3ME2xPFAvOyCwTR?=	NFTwUXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SNU-C2B	M3\wXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnjRmRKSzVyPUG4NE44OyCwTR?=	M2HWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A427	NVj0UFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;iU\|RKSzVyPUG4Nk42PyCwTR?=	NVi3b\|BPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KP-N-YS	M1fITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fweGlEPTB;MUi1JI5O	NE\2S\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
J82	NGTme4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fJW2lEPTB;MUi1MlE5KG6P	M2LGV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LS-411N	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e5S2lEPTB;MUi3MlI5KG6P	NWG3UoRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC1937	M17VWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoruTWM2OD1zOEeuOFkhdk1?	NFf1dWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OE33	M4j1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\t[nBVUUN3ME2xPFgvQTdibl2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB7	NE\LVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TBVmlEPTB;MUi5Mlg6KG6P	MnTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW684	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF7Nj6xN{BvVQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HT-144	NILJRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjhTWM2OD1zOU[uNVUhdk1?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-MEL-30	M1LPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M365W2lEPTB;MUm2MlIhdk1?	MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DBTRG-05MG	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7kTWM2OD1zOUiuOFchdk1?	NVzyN5VXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1395	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWToTpUxUUN3ME2xPVgvQDVibl2=	NXy3bFBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2122	M2TFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFryZppKSzVyPUKwNE42QSCwTR?=	Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
no-10	NF\MPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofaTWM2OD1{MEGuNFQhdk1?	NFPyWWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW48	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PxfGlEPTB;MkCxMlMyKG6P	NWCzXZpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1650	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrv[HA3UUN3ME2yNFQvODFibl2=	NEXwRYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MZ1-PC	M2PVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoL0TWM2OD1{MEWuOVghdk1?	NH36U2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
U-266	M2L5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXoT3Y6UUN3ME2yNFUvPzlibl2=	NELkUYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAS-1	NVvKV3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37GeWlEPTB;MkC3MlQ1KG6P	M17rRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
AU565	NFriOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjXfVNKSzVyPUKxNk45OiCwTR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
UACC-257	NUjlRWloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\IelZ5UUN3ME2yNVMvQTlibl2=	M1jiOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-27	NFX1XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTJzNz6wOUBvVQ>?	NFTpbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H23	NVPEcIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJzOT6zN{BvVQ>?	M{TtUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-6	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Cw[2lEPTB;MkG5MlY5KG6P	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJ{Mj6xO{BvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-1	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDleIJDUUN3ME2yNlIvQDhibl2=	NXO0OVhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RCC10RGB	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3FNo1KSzVyPUKyOE4yQSCwTR?=	NUfPT4hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H596	M17tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4qwO2lEPTB;MkK4MlIzKG6P	MkDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW954	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TKc2lEPTB;MkOzMlg{KG6P	NYXIboIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2087	NWfhSlNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLBSmR4UUN3ME2yN\|QvPTFibl2=	M3XrO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-PN-DW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrQTWM2OD1{M{WuNVkhdk1?	M{PiclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KM12	M1vh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnH1TWM2OD1{M{WuO{BvVQ>?	MlrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BT-474	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fOemlEPTB;MkO1Mlc{KG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IST-MES1	M{PSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4juUWlEPTB;MkO2MlU4KG6P	MnP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HT-1197	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJ\|OD6wPUBvVQ>?	NFz0R\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-54	M2LObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jyfGlEPTB;MkO4MlQ6KG6P	MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB10	NVPFR4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7GUGpKSzVyPUK0NE4xPiCwTR?=	NGjPS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PANC-10-05	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrIfIVKSzVyPUK0OU42PiCwTR?=	M3nMPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H522	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXeyRZNXUUN3ME2yOFgvOzFibl2=	NVewT3VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A388	NIr0SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPTPZYxUUN3ME2yOFkvQDJibl2=	M4PXXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GOTO	NUmz[oxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X0V2lEPTB;MkWwMlI6KG6P	NXXwXY1mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fjd2lEPTB;MkWxMlg4KG6P	NIHOeGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-520	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJ3Mj64OkBvVQ>?	Mo\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCE-4	M{HsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfvRpVwUUN3ME2yOlIvPSCwTR?=	NWXVepRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KURAMOCHI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHqWm9bUUN3ME2yOlUvQSCwTR?=	MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC38	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13ZfGlEPTB;Mk[2MlQ5KG6P	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
FADU	M3LiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;6TWM2OD1{Nk[uOlMhdk1?	NHrGdnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CW-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPpc3JKSzVyPUK2PU46PiCwTR?=	M4TidlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
L-428	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\pRWlEPTB;Mke1MlE2KG6P	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCC1569	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\Xe3RKSzVyPUK3OU45PCCwTR?=	NVfnXJFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H810	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7QWm11UUN3ME2yO\|gvOzFibl2=	MmLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB771-HNC	M37idWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LWZ2lEPTB;Mki1Mlg1KG6P	NILMTZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LCLC-103H	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJ6NT65PUBvVQ>?	M1vQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EFO-21	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXOWVJKSzVyPUK4O{43QCCwTR?=	NVrjWXhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-72	NFTBd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrNcXRKSzVyPUK5N{4yQSCwTR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SCC-9	M1ruWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTJ7Mz6yNkBvVQ>?	M4DnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COLO-829	NXHh[4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJ7Nj61JI5O	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
U-87-MG	NH[5OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPNPVZxUUN3ME2zNFAvPzNibl2=	MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MZ7-mel	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYe5UYhsUUN3ME2zNlMvPzZibl2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1770	M2K4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TMSmlEPTB;M{K2Mlc1KG6P	M4\pW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ChaGo-K-1	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFSzbGVKSzVyPUOyPE4yKG6P	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SiHa	M2O5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonGTWM2OD1\|MkmuNlQhdk1?	NYLhdVNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-SNU-5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTN\|Nj63O{BvVQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DJM-1	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXuUphmUUN3ME2zOFAvOzNibl2=	NXi3dYNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OE19	M2Xacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHaNWJKSzVyPUO0NE42OyCwTR?=	M1L2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1651	NIfXXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoH4TWM2OD1\|NESuNVghdk1?	MoS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-792	NG\henZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rVNWlEPTB;M{W0MlQzKG6P	NYPvVZZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ACHN	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrTZ5ZIUUN3ME2zOVYvPzFibl2=	NV3FZZdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TH-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LRNmlEPTB;M{e5Mlk2KG6P	M1K4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HT-1376	M3HJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7oXGFKSzVyPUO4OE45QCCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RH-18	NXLpfIRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;3TWM2OD1\|OUSuO\|Qhdk1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB6	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULLO4VoUUN3ME2zPVYvPjZibl2=	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-320-HSR	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrEOo5KSzVyPUSwN{4{PyCwTR?=	NGXv[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
UACC-893	NU\XfoZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XpTGlEPTB;NEC2MlQ4KG6P	M3;pTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DSH1	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlX4TWM2OD12ME[uPVEhdk1?	MkK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TE-10	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLnfZBKUUN3ME20NFcvODFibl2=	M2fPblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCC70	M33Pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTRyOT6yNUBvVQ>?	NW\Vb\|dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TGBC11TKB	NEHtfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7FTWM2OD12MUCuN\|Mhdk1?	NF7uTHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H727	NUfjfW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLRc\|BKSzVyPUSxNk4yOSCwTR?=	NYnqOllDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ALL-PO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTRzNT62PUBvVQ>?	M1PQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ABC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3HdINWUUN3ME20NlAvPDVibl2=	NFPLRpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H69	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTxUmNKSzVyPUSyOk44PiCwTR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GP5d	NH24NnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTR\|ND60NUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
UMC-11	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTR3OD6zOkBvVQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RMG-I	NGHs[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETx[GFKSzVyPUS2O{42PiCwTR?=	M{jNcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
YAPC	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrPXIdbUUN3ME20PVAvPiCwTR?=	NX;TUVlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-1034	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTsd4tpUUN3ME20PVEvODZibl2=	NIXvbnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RCM-1	NYD2[5ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTR7Nj62PEBvVQ>?	MknLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1954	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7pd5FKSzVyPUWxNk42KG6P	NFixfo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-24	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK1TWM2OD13MU[uOVEhdk1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB12	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTV{OD60NkBvVQ>?	NXvEWopvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW756	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLqTWM2OD13NUSuPVYhdk1?	Ml;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1187	NVm4c3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHMboZFUUN3ME21O\|UvQDNibl2=	MkDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2342	NIfKVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTV7MD6zPUBvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2291	NInYOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfzUnhXUUN3ME21PVgvOzFibl2=	NWrk[m8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OVCAR-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLUeHY1UUN3ME21PVgvQTZibl2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTZ{OT6wNUBvVQ>?	NHjOU3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SAS	M1\Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LNcWlEPTB;NkWyMlY4KG6P	NVm0NIlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-824	NFjScIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTSWHFDUUN3ME22PFkvOzdibl2=	NUP6OW01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC1395	NVjhdZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnyyTWM2OD14OUiuOUBvVQ>?	NGTmcm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-668	NHWxbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjVdnhKSzVyPUewOk4yKG6P	M3LROVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H226	M2HNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHlTWM2OD15MEeuPEBvVQ>?	Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB17	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDEOVJKSzVyPUeyNU44PSCwTR?=	MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1463	NVfqTG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDLN2pKSzVyPUezPU4yQSCwTR?=	NUH0bFZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TGW	NHP3dYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvtTWM2OD15NkCuNVUhdk1?	MlHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H526	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPue2FKSzVyPUiyN{42OyCwTR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COR-L88	NYjzfZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLrTWM2OD16NEiuNVIhdk1?	MkTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H441	M2XzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7sZ2hKSzVyPUi5OU4zOiCwTR?=	NVzmSFJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H630	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TWcGlEPTB;OUGyMlk3KG6P	MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Mo-T	NH7qVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPxN5ZKSzVyPUm0O{45QCCwTR?=	NEjIbHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
JAR	NXHxNI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljXTWM2OD17NU[uNlQhdk1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1838	NGLIR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLETWM2OD1zLkCyN\|g5KM7:TR?=	NEHleW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DoTc2-4510	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe0PHhjUUN3ME2xMlA4Ozd4IN88US=>	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MKN28	M1rtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{WxZmlEPTB;MT6wPVAzPCEQvF2=	M3fXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuP-T3	NXHFdJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LQ[mlEPTB;MT6xNVkxPSEQvF2=	M2nUflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-9	M{nuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLle\|JKSzVyPUGuNVI6PzNizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NY	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fWeWlEPTB;MT6xOlc6OiEQvF2=	M1SzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HT55	NYTRcolUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwM{GzOFQh\|ryP	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW837	NWjTZ3k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWToTVFwUUN3ME2xMlMzQTd6IN88US=>	M{f3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2029	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYO0dGRDUUN3ME2xMlQyPzlzIN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IST-SL1	NVPWN4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwNESyOEDPxE1?	NITQS4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-741	M1jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTuWnRKSzVyPUGuOFk4PzFizszN	NHjNVm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LU-65	NF\5XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP4NZhKSzVyPUGuOlIzPDlizszN	NETVSHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1304	M4G3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TZSWlEPTB;MT62OVQ6QCEQvF2=	MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KARPAS-299	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XwZWlEPTB;MT63PVQ4QSEQvF2=	NWrofWZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H358	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fqV2lEPTB;MT65OVUxOyEQvF2=	M3fIfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OAW-28	NXHvc\|lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzOWZhKUUN3ME2yMlA3QTF7IN88US=>	MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
C8166	NXO1OYJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofaTWM2OD1{Lk[zN\|kzKM7:TR?=	NXi2VYRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-678	M2fuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHOdXRKSzVyPUKuPFM4PjhizszN	MmjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-N-DZ	M2fveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJwOE[zPFEh\|ryP	NFnh[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H82	NXqx[2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHETWM2OD1{LkmwN\|Y6KM7:TR?=	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
JVM-2	M4jsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETUN2JKSzVyPUOuNFMyQDhizszN	M4KxU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1116	NF;nT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTNwMEW0NVEh\|ryP	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-453	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfTSnFKSzVyPUOuNVA1OzlizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Calu-6	NUO5[oJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{P5RWlEPTB;Mz6xPVk4KM7:TR?=	NVXVXFhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SHP-77	NWq5dmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnPUXhKSzVyPUOuOVI5KM7:TR?=	NGTaOmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Capan-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTRwM{K1PFEh\|ryP	M4TvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW948	M{L2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLLTWM2OD12Lke0O\|c6KM7:TR?=	NH3ZO5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HDLM-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTYbmpKSzVyPUWuNFc4OjVizszN	M{XtPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LAN-6	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTZwMkG0PVUh\|ryP	NXzGfWZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LU-135	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPzTWM2OD14LkSzNFc4KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
T84	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnnTWM2OD14Lkm4OlQh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAPAN-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfTbHRtUUN3ME23MlYzOjN\|IN88US=>	NYLQboJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1417	M2POcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTdwOUG3N\|Eh\|ryP	Mkj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BALL-1	NFv1Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRThwNUC0NFkh\|ryP	NWfqcWNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-29	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTlwMEe1PVkh\|ryP	M{D1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C3A	NF3LfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3xWFBKSzVyPUmuPFg{QTRizszN	MlzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1993	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[wWmlEPTB;MUCuOVA5OSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTFzLk[yPFkh\|ryP	NFXxOnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DU-145	M4mxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7xfY15UUN3ME2xOE42ODV{IN88US=>	M2[2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KP-N-YN	NVK1TYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPNTWM2OD1zND61NVA{KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NYjpZ5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX3eXdKSzVyPUG0Mlc5ODlizszN	M3HVeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ZR-75-30	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITSfoxKSzVyPUG2MlM{ODNizszN	NIH0O5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A673	NWTDXGJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2q4O2lEPTB;MkCuOVUxPyEQvF2=	NF76U\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
K-562	NV:4RnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;Oc2JKSzVyPUK4MlQyQDNizszN	M4nS[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BEZ235
Smiles	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)